Search results
Results From The WOW.Com Content Network
The incidence of TA-GvHD in immunocompromised patients receiving blood transfusions is estimated to be 0.1–1.0%, and mortality around 80–90%. Mortality is higher in TA-GvHD than in GvHD associated with bone marrow transplantation , where the engrafted lymphoid cells in the bone marrow are of donor origin (in autotransplant) and therefore ...
The symptoms of TACO can include shortness of breath , low blood oxygen levels , leg swelling (peripheral edema), high blood pressure (hypertension), and a high heart rate (tachycardia). [ 3 ] It can occur due to a rapid transfusion of a large volume of blood but can also occur during a single red blood cell transfusion (about 15% of cases). [ 2 ]
Post-transfusion purpura (PTP) is a delayed adverse reaction to a blood transfusion or platelet transfusion that occurs when the body has produced alloantibodies to the allogeneic transfused platelets' antigens. These alloantibodies destroy the patient's platelets leading to thrombocytopenia, a rapid decline in platelet count. [1]
Comparison of symptoms of blood transfusion reactions characterized by fever. [45] + =Occasionally present ++ =Frequently present Febrile nonhemolytic TRALI Acute hemolytic Bacterial contamination Appearance of symptoms during or after transfusion Usually toward end. 5–10% appear up to 2 hours after. Early (after 10–15 ml) Early (after 50 ...
Transfusion-dependent anemia is a form of anemia characterized by the need for continuous blood transfusion. It is a condition that results from various diseases, and is associated with decreased survival rates. [1] [2] Regular transfusion is required to reduce the symptoms of anemia by increasing functional red blood cells and hemoglobin count.
Febrile non-hemolytic transfusion reaction (FNHTR) is the most common type of transfusion reaction. It is a benign occurrence with symptoms that include fever but not directly related with hemolysis. [1] It is caused by cytokine release from leukocytes within the donor product as a consequence of white blood cell breakdown.
Transfusion hemosiderosis can cause permanent damage to tissues that may lead to death. [2] Tissue damage can remain even after chelation therapy. [2] Outcomes are usually worse in patients who require blood transfusions compared to those who can have alternative therapies. [2] Cardiomyopathy and cardiac arrhythmia are often a cause of death. [1]
It is often impossible to distinguish TRALI from acute respiratory distress syndrome (ARDS). The typical presentation of TRALI is the sudden development of shortness of breath, severe hypoxemia (O 2 saturation <90% in room air), low blood pressure, and fever that develop within 6 hours after transfusion and usually resolve with supportive care within 48 to 96 hours.